Nufymco (ranibizumab-leyk) NDC 70710-2173

NDC codes

FDA NDC Directory

Product NDC (as listed)70710-2173Labeler and product segments. Claims need a package NDC.

Product NDC at billing width70710-2173Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
70710-2173-1	70710217301	1 VIAL, GLASS in 1 CARTON (70710-2173-1) / .05 mL in 1 VIAL, GLASSMarketed from Jun 11, 2026

How the 11-digit form is made: The package segment has 1 digit, so one leading zero is added to it (5-4-1 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Nufymco
Generic name (nonproprietary): ranibizumab-leyk
Active ingredients: Ranibizumab — .5 mg/.05mL
Dosage form: Injection, Solution
Route: Intravitreal
Labeler: Zydus Pharmaceuticals USA Inc.
Product type: Prescription drug
Marketing category: BLA — Biologics License ApplicationApplication BLA 761473
Marketing start: Jun 11, 2026
Listing expires: Dec 31, 2027
Other FDA classes: Vascular Endothelial Growth Factor Inhibitors (Mechanism)
Identifiers: Product ID 70710-2173_4a45dd5a-c8d9-4e98-9586-ab6c069c2ffeSPL ID 4a45dd5a-c8d9-4e98-9586-ab6c069c2ffeSPL set ID 05ed75bc-ae21-480b-9be4-cbc51689dd8aRxCUI 2744887, 2744894, 2744897, 2744900UNII ZL1R02VT79UPC 0370710217310
Pharmacologic class: Vascular Endothelial Growth Factor Inhibitor

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeMed-Code curated

J2778 — Injection, ranibizumab, 0.1 mg

Billing unit: 0.1 mg. Units on the claim = dose given ÷ 0.1 mg.

Ranibizumab biosimilars and the ranibizumab implant have their own HCPCS codes.

Administration

Intravitreal injection procedure (CPT 67028)

The intravitreal injection is reported as a separate procedure from the drug supplied.

How CPT relates to drug billing

NDC on a medical claim

N470710217301 followed by a unit qualifier and the quantity

Package 70710-2173-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Jun 4, 2026.

Indications (excerpt from the label)

NUFYMCO is indicated for the treatment of patients with: NUFYMCO, a vascular endothelial growth factor (VEGF) inhibitor, is indicated for the treatment of patients with: Neovascular (Wet) Age-Related Macular Degeneration (AMD) ( 1.1 ) Macular Edema Following Retinal Vein Occlusion (RVO) ( 1.2 ) Diabetic Macular Edema (DME) ( 1.3 ) Diabetic Retinopathy (DR) ( 1.4 ) Myopic Choroidal Neovascularization (mCNV) ( 1.5 ) 1.1 Neovascular (Wet) Age-Related Macular Degeneration (AMD) 1.2 Macular Edema Following Retinal Vein Occlusion (RVO) 1.3 Diabetic Macular Edema (DME) 1.4 Diabetic Retinopathy (DR) 1.5 Myopic Choroidal Neovascularization (mCNV)

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under BLA 761473

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under BLA 761473
Product	Strength	Form · route	Labeler	Product NDC
Nufymcoranibizumab-leyk	Ranibizumab .3 mg/.05mL	Injection, SolutionIntravitreal	Zydus Pharmaceuticals USA Inc.	70710-2172